Equities research analysts expect Applied Genetic Technologies Corporation (NASDAQ:AGTC) to announce earnings per share (EPS) of $0.11 for the current quarter, Zacks reports. Four analysts have provided estimates for Applied Genetic Technologies Corporation’s earnings, with estimates ranging from ($0.09) to $0.65. Applied Genetic Technologies Corporation reported earnings of $0.15 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 26.7%. The business is scheduled to announce its next earnings results on Monday, September 11th.

According to Zacks, analysts expect that Applied Genetic Technologies Corporation will report full year earnings of $0.32 per share for the current financial year, with EPS estimates ranging from $0.06 to $0.89. For the next financial year, analysts forecast that the business will report earnings of ($0.22) per share, with EPS estimates ranging from ($1.11) to $0.52. Zacks’ EPS averages are a mean average based on a survey of analysts that cover Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by $0.04. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. The firm had revenue of $8.39 million for the quarter, compared to analyst estimates of $10.39 million. During the same period last year, the company earned $0.11 EPS. The company’s revenue was down 30.1% compared to the same quarter last year.

AGTC has been the subject of several recent research reports. Stifel Nicolaus decreased their price objective on Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, May 11th. HC Wainwright set a $16.00 price objective on Applied Genetic Technologies Corporation and gave the company a “buy” rating in a report on Thursday. ValuEngine downgraded Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research downgraded Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Finally, Cantor Fitzgerald set a $15.00 price objective on Applied Genetic Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, May 10th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $13.81.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded up 1.00% during trading on Thursday, reaching $5.05. The company’s stock had a trading volume of 146,484 shares. The company’s 50-day moving average is $4.99 and its 200-day moving average is $6.10. Applied Genetic Technologies Corporation has a 12 month low of $4.50 and a 12 month high of $15.78. The stock has a market cap of $91.28 million, a PE ratio of 12.05 and a beta of 1.68.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/10/0-11-eps-expected-for-applied-genetic-technologies-corporation-agtc-this-quarter.html.

A number of large investors have recently made changes to their positions in AGTC. Trexquant Investment LP increased its stake in shares of Applied Genetic Technologies Corporation by 3.2% in the second quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 611 shares during the period. CAPROCK Group Inc. increased its stake in shares of Applied Genetic Technologies Corporation by 55.8% in the first quarter. CAPROCK Group Inc. now owns 17,215 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 6,165 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Applied Genetic Technologies Corporation during the first quarter valued at about $123,000. Wells Fargo & Company MN increased its stake in shares of Applied Genetic Technologies Corporation by 1.1% in the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 200 shares during the period. Finally, Smith Asset Management Group LP bought a new stake in shares of Applied Genetic Technologies Corporation during the first quarter valued at about $141,000. Institutional investors and hedge funds own 62.22% of the company’s stock.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Get a free copy of the Zacks research report on Applied Genetic Technologies Corporation (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.